[1] National Health Commission on People's Republic of China. Notice on printing and distributing opinions on strengthening pharmaceutical nanagement in nedical institutions to promote rational drug use[EB/OL]. 2020 [2020-02-29]. http://www.nhc.gov.cn/yzygj/s7659/202002/ea3b96d1ac094c47a1fc39cf00f3960e.shtml.
[2] NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Guidelines for the clinical application of new anti-tumor drugs (2018 edition) [J]. J Multidisciplinary Cancer Manag (Electronic Version), 2019, 5(1):35-54.
[3] NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Notice on issuing guidelines for clinical application of new antitumor drugs (2019 edition) [EB/OL]. 2020 [2020-02-29]. http://www. nhc. gov. cn/yzygj/s7659/201912/3922e93c3ef84c54879f36777db73568. shtml.
[4] LI G H, DONG M, CHEN Z, et al. Expert consensus on prescription verification for anti-tumor drugs-colorectal cancer [J]. Chin Pharm J(中国药学杂志), 2019, 54(16):1361-1366.
[5] LI G H, HAO Z Y, CHEN Z, et al. Expert consensus on prescription verification for anti-tumor drugs-liver cancer [J]. Chin Pharm J(中国药学杂志), 2019, 54(18):1539-1542.
[6] LI G H, YANG J, DAI Z, et al. Expert consensus on prescription verification for anti-tumor drugs-lung cancer [J]. Chin Pharm J(中国药学杂志), 2019, 54(10):847-854.
[7] NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN chemotherapy order templates (NCCN Templates^®) appendix B [EB/OL]. [2020-03-08]. https://www. nccn. org/professionals/OrderTemplates/PDF/appendix_B. pdf.
[8] NGUYEN J, SOLIMANDO D J, WADDELL J A. Carboplatin and liposomal doxorubicin for ovarian cancer[J]. Hosp Pharm, 2016, 51(6):442-449.
[9] DOOLEY M J, POOLE S G, RISCHIN D, et al. Carboplatin dosing[J]. Eur J Cancer, 2002, 38(1): 44-51.
[10] DRUG-INDUCED LIVER INJURY GROUP OF THE CHINESE SOCIETY OF HEPATOLOGY. Guidelines for the diagnosis and treatment of drug-induced liver injury [J]. Chin J Viral Dis, 2015, 5(5):321-341.
[11] YU Y C, MAO Y M, CHEN C W, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3):221-241.
[12] EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019, 70(6):1222-1261.
[13] YU S Y, YAO Y. Expert Consensus on the Prevention and Treatment of Anti-Tumor Drug-Related Liver Injury(肿瘤药物相关性肝损伤防治专家共识)[M]. 2014. Beijing: Peking Union Medical College Press.
[14] JIA H J, ZHENG X H, ZHAO Z Y. Interpretation of the new edition of "Guiding principles for the clinical application of antibacterial Drugs (2015)" [J]. Tianjin Pharm(天津药学), 2016, 28(5):46-48.
[15] NATINAL HEALTH AND FAMILY PLANNING COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Guidelines for clinical application of antimicrobial drugs issued (2015 edition) [J]. Chin Med Biotechnol(中国医药生物技术), 2015, 10(5):477.
[16] NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN clinical practice guidelines in oncology: cervical cancer(2020.V1) [EB/OL]. (2020-01-14) [2020-03-08]. https://www.nccn.org/professionals/physician_gls/default.aspx.
[17] NATIONAL COMPREHENSIVE CANCER NETWORK.NCCN clinical practice guidelines in oncology: uterine neoplasms(2019. V5) [EB/OL]. 2019 [2020-03-08]. https://www.nccn.org/professionals/physician_gls/default.aspx.
[18] ZHEN Z, SUN X, HE Y, et al. The sequence of drug administration influences the antitumor effects of bevacizumab and cyclophosphamide in a neuroblastoma model[J]. Med Oncol, 2011, 28(suppl 1):S619-S625.
[19] Cervical advanced cARBOplatin, PACLitaxel and bevacizumab[EB/OL].1989 (2018-01-11) [2020-02-27]. https://www.eviq.org.au/medical-oncology/gynaecological/cervical/1989-cervical-advanced-carboplatin-paclitaxel-and.
[20] OZA A M, COOK A D, PFISTERER J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7):overall survival results of a phase 3 randomised trial[J]. Lancet Oncol, 2015, 16(8):928-936.
[21] MEDICAL RESEARCH COUNCIL.Carboplatin and paclitaxel with or without bevacizumab in treating patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer[EB/OL]. 2012 [2020-03-08]. https://clinicaltrials. gov/ct2/show/record/NCT00483782?term=ISRCTN91273375& draw=2&rank=1.
[22] RECK M, BONDARENKO I, LUFT A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial[J]. Ann Oncol, 2013, 24(1):75-83.
[23] OGAWARA D, SODA H, IWASAKI K, et al. Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy[J]. Thorac Cancer, 2018, 9(1):175-180.
[24] PARK S E, LEE S H, AHN J S, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2018, 13(1):106-111.
[25] CANCER COUNCIL AUSTRALIA. Non small cell lung cancer metastatic cARBOplatin, PACLitaxel and pembrolizumab[EB/OL]. 2018 [2020-03-08]. https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer/3502-nsclc-metastatic-carboplatin-paclitaxel-and-p#interactions.
[26] MERCK SHARP & DOHME CORP. A study of carboplatin-paclitaxel/Nab-paclitaxel chemotherapy with or without pembrolizumab (MK-3475) in adults with first line metastatic squamous non-small cell lung cancer (MK-3475-407/KEYNOTE-407) [EB/OL]. 2018 [2020-03-08]. https://clinicaltrials.gov/ct2/show/NCT 02775435.
[27] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051.
[28] JI X Y. The contraindications for the combination of multiple trace element injection (Ⅱ) and vitamin B6 [J]. Clin J Med Off, 2011, 39(5):838.
[29] LI X Y, PAN Y, WEI X, et al. Investigation and analysis of the use of antibacterial drugs in patients with gynecological tumors during perioperative period [J]. Pharm Today, 2016, 26(10):724-727.
[30] WEI N, WENG X H, ZENG F X, et al. The entry point for clinical pharmacists to participate in medical oncology rounds under the precision medicine system [J]. Chin J Clin Pharm, 2019, 28(5):382-384.
[31] SON H, KIM J, KIM C, et al. Pharmacist-led interdisciplinary medication reconciliation using comprehensive medication review in gynaecological oncology patients: a prospective study[J]. Eur J Hosp Pharm, 2018, 25(1):21-25.
[32] HANSEN E A, PIETKIEWICZ J M, BLUM B L. Evaluation of the feasibility and utility of a pharmacist-centered collaborative drug therapy management program for oncology-based symptom management[J]. J Pharm Pract, 2016, 29(3):206-211.
[33] CONLIFFE B, FIGG L, MOFFETT P, et al. Impact of a formal pharmacist-run oral antineoplastic monitoring program: a pilot study in an adult genitourinary oncology clinic[J]. J Oncol Pharm Pract, 2019, 25(4):777-786.
[34] YOKOYAMA S, YAJIMA S, SHIMAUCHI A, et al. Oncology pharmacist contributions to treatment with oral anticancer agents in a Japanese community pharmacy setting[J]. Can Pharm J (Ott), 2018, 151(6):377-382.
[35] CURRY M A, CHINEKE I, REDELICO T, et al. Adherence to oral anticancer medications after implementation of an ambulatory adherence program at a large urban academic hospital[J]. J Oncol Pract, 2020, 16(4):e350-e356.